What’s the Half-Life of Melatonin? (Metabolism Explained)

What's the Half-Life of Melatonin? (Metabolism Explained)

Most people assume melatonin lingers in the body for hours, slowly releasing sedation throughout the night. It doesn't. Melatonin's half-life. The time it takes for half the dose to be metabolised and cleared from your bloodstream. Ranges from 30 to 60 minutes in healthy adults. Within 3–5 hours of ingestion, plasma melatonin levels return to near baseline, which explains why melatonin supplementation works primarily for initiating sleep, not maintaining it. This short elimination timeline fundamentally changes how you should think about dosing, timing, and why simply increasing the dose won't extend its effect.

Our experience reviewing research-grade peptide compounds used in metabolic and circadian studies has clarified a persistent misunderstanding: melatonin's effectiveness isn't about sustained serum concentration. It's about correctly timed receptor activation. The gap between taking melatonin correctly and wasting it comes down to three factors most supplement guides ignore: pharmacokinetic variability, hepatic first-pass metabolism, and the difference between physiological and pharmacological dosing.

What's the half-life of melatonin, and why does it matter for supplementation?

Melatonin has a plasma half-life of approximately 30–60 minutes in most adults, meaning that within 3–5 hours, over 95% of an oral dose is metabolised and eliminated. This rapid clearance occurs primarily in the liver via CYP1A2 enzyme-mediated hydroxylation into 6-hydroxymelatonin, which is then conjugated and excreted in urine. The practical implication: melatonin supplementation is most effective when timed 30–60 minutes before intended sleep onset, not hours in advance or sporadically throughout the day.

The direct answer most supplement labels won't tell you: melatonin's short half-life means it works through receptor activation signalling. Not prolonged sedation. Endogenous melatonin (produced naturally by the pineal gland) follows a predictable circadian rhythm: levels begin rising around 9–10 PM, peak between 2–4 AM, and decline rapidly by morning. When you supplement exogenously, you're not replacing this entire curve. You're mimicking the early rise that tells your suprachiasmatic nucleus (SCN) in the hypothalamus that it's time to initiate sleep physiology. This article covers the pharmacokinetics that determine melatonin's duration of action, how individual variability affects elimination rates, and what dosing patterns actually align with the compound's metabolic profile.

How Melatonin Is Metabolised in the Body

Melatonin metabolism begins the moment it's absorbed into the bloodstream. Following oral administration, melatonin undergoes hepatic first-pass metabolism. Meaning it passes through the liver before reaching systemic circulation. The cytochrome P450 enzyme CYP1A2 is the primary enzyme responsible for melatonin hydroxylation, converting it into 6-hydroxymelatonin. This metabolite is then conjugated with sulfate or glucuronide and excreted primarily through urine. This entire hepatic pathway is why bioavailability of oral melatonin is relatively low. Typically 10–56% depending on formulation, individual liver enzyme activity, and concurrent medication use.

The enzyme responsible for most melatonin breakdown. CYP1A2. Exhibits significant inter-individual variability. Genetic polymorphisms in the CYP1A2 gene can result in fast or slow metaboliser phenotypes, which directly affects how quickly melatonin is cleared. Fast metabolisers may see a half-life closer to 30 minutes, while slow metabolisers can extend it to 60–90 minutes. Additional factors that inhibit CYP1A2 include fluvoxamine (a selective serotonin reuptake inhibitor), ciprofloxacin (an antibiotic), and even grapefruit juice. All of which can substantially prolong melatonin's half-life and increase plasma concentration unexpectedly. Conversely, smoking induces CYP1A2 activity, accelerating melatonin clearance.

Formulation also influences absorption kinetics. Immediate-release tablets and sublingual forms produce peak plasma concentration (Cmax) within 30–60 minutes, followed by rapid decline. Extended-release formulations attempt to delay absorption through layered coatings or matrix delivery systems, extending the release window to 6–8 hours. Though the underlying half-life of melatonin itself remains unchanged. The extended formulation doesn't slow metabolism; it slows release into the bloodstream. Once absorbed, melatonin is metabolised at the same rate regardless of whether it came from an immediate or extended-release tablet. Research compounds like Semax Nasal Spray and Selank Nasal Spray similarly demonstrate how formulation route. Nasal mucosa vs oral absorption. Affects bioavailability and plasma concentration kinetics without altering the intrinsic half-life of the active peptide.

Why the Half-Life of Melatonin Explains Dosing Patterns

The 30–60 minute half-life of melatonin dictates optimal dosing strategy in ways most supplement users don't consider. Because plasma melatonin peaks within one hour and declines rapidly, timing matters more than dose size. A 0.3 mg dose taken 45 minutes before bed produces similar sleep-onset effects as a 5 mg dose taken at the same time. Because both activate MT1 and MT2 melatonin receptors during the critical circadian window. What differs is the magnitude and duration of receptor saturation, not the sleep-initiating signal itself.

Physiological melatonin levels. The concentration naturally produced by your pineal gland at night. Range from 60–150 pg/mL at peak. Most commercial supplements contain 1–10 mg per dose, which produces pharmacological plasma levels (300–3000 pg/mL) far exceeding endogenous production. These supraphysiological doses don't proportionally improve sleep quality; they saturate receptors beyond the threshold needed for circadian phase shifting. Research from MIT published in the Journal of Clinical Endocrinology & Metabolism found that doses as low as 0.3 mg were sufficient to achieve physiological plasma concentrations that effectively reduced sleep latency. Higher doses simply prolonged receptor occupancy without additional benefit and increased next-day residual sedation.

Our team has observed this consistently across research protocols: exceeding physiological receptor activation thresholds introduces diminishing returns. The melatonin receptor doesn't respond to "more is better" pharmacology the way, for instance, GLP-1 receptor agonists do with dose-dependent weight loss. Instead, melatonin operates on a binary activation model. Receptors either signal circadian phase shift or they don't. Once MT1 and MT2 receptors in the SCN are activated, additional melatonin binding to those receptors doesn't amplify the sleep signal; it just extends the duration of receptor occupancy, which may paradoxically delay morning wakefulness or create grogginess. This is mechanistically distinct from compounds in metabolic research stacks like MOTS-C Nasal Spray, where dose escalation corresponds to measurable changes in mitochondrial function and energy expenditure.

What's the Half-Life of Melatonin: Individual vs Population Variability

The population average of 30–60 minutes masks substantial individual variability. Genetic testing for CYP1A2 phenotype isn't standard practice in sleep medicine, but its impact is measurable. A 2014 study in Clinical Pharmacology & Therapeutics demonstrated that CYP1A2 slow metabolisers exhibited melatonin AUC (area under the curve) values 2–3 times higher than fast metabolisers at identical doses. Meaning slow metabolisers sustained higher plasma concentrations for longer despite the same nominal half-life. This variability explains why some users report next-day grogginess (slow metabolisers taking excessive doses) while others report no effect (fast metabolisers or poor timing).

Age-related changes also modify melatonin pharmacokinetics. Prepubertal children exhibit faster melatonin clearance relative to body weight, likely due to higher hepatic enzyme activity per kilogram. Conversely, adults over 65 often show prolonged half-lives due to reduced CYP1A2 expression and declining renal function, which slows the elimination of melatonin metabolites. The FDA has not established paediatric dosing guidelines for melatonin supplements, and variability in clearance rates complicates standardised recommendations. This is one reason why melatonin remains classified as a dietary supplement rather than a regulated pharmaceutical in most jurisdictions.

What If: Melatonin Half-Life Scenarios

What If I Take Melatonin Too Early — Will It Still Work?

Taking melatonin 3–4 hours before bed may initiate drowsiness prematurely, but the compound will be mostly cleared by your intended bedtime. The circadian phase-shifting effect requires melatonin receptor activation during the biological evening. The window when endogenous melatonin would naturally begin rising. If you dose too early, you risk mis-timing the signal: you'll feel transiently drowsy while plasma levels are elevated, then alert again once melatonin clears, defeating the purpose. The optimal window is 30–60 minutes before you intend to fall asleep, not before you begin your bedtime routine.

What If I'm a CYP1A2 Slow Metaboliser — Should I Adjust My Dose?

Slow metabolisers experience prolonged melatonin clearance, which means standard 3–5 mg doses produce plasma concentrations that persist well into the morning. This manifests as next-day grogginess, cognitive fog, or difficulty waking. If you suspect slow metabolism (family history of drug sensitivity, known CYP1A2 polymorphism, or consistent reports of melatonin 'hangover'), start with 0.3–0.5 mg and assess response. Genetic testing for CYP1A2 phenotype is available through commercial panels, though not typically covered by insurance. Adjusting dose downward is safer than assuming standard dosing applies universally.

What If I Take Melatonin with an SSRI — Is That Safe?

Fluvoxamine, a selective serotonin reuptake inhibitor, is a potent CYP1A2 inhibitor that can increase melatonin AUC by up to 17-fold. This interaction is clinically significant and creates risk of profound sedation, hypotension, and prolonged cognitive impairment. If you're prescribed fluvoxamine, melatonin supplementation should be discussed with your prescribing physician. Not self-managed. Other SSRIs (sertraline, escitalopram) have weaker CYP1A2 interactions, but concurrent use still warrants caution. Always disclose supplement use during medication reviews; the half-life of melatonin assumes normal hepatic metabolism, which SSRIs disrupt.

The Blunt Truth About Melatonin's Half-Life

Here's the honest answer: the 30–60 minute half-life means melatonin isn't the all-night sleep aid most marketing implies. It's a circadian phase-shifter. A biological alarm clock reset, not a sedative. If you're waking at 3 AM or struggling with sleep maintenance, melatonin won't solve that problem because it's already metabolised and cleared by then. The compound works by telling your brain it's time to initiate sleep, not by keeping you asleep once that process starts. Extended-release formulations attempt to address this gap, but they're still constrained by the same underlying pharmacokinetics: once absorbed, melatonin is cleared rapidly regardless of how slowly it was released.

Most sleep issues attributed to "melatonin not working" are actually mis-dosing or mis-timing errors. Taking 10 mg at bedtime doesn't produce 10 times the effect of 1 mg. It produces receptor saturation followed by prolonged morning grogginess. The effective therapeutic dose aligns with physiological receptor activation thresholds (0.3–1 mg for most adults), not with the oversized doses marketed for consumer appeal. If standard-dose melatonin taken at the correct time (45–60 minutes pre-sleep) doesn't reduce sleep latency, the issue is likely not melatonin deficiency. It's circadian misalignment, sleep hygiene failure, or an underlying sleep disorder that requires medical evaluation, not higher supplement doses. Research peptides addressing circadian and metabolic pathways, like those in our Sleep Stack or Cognitive Function formulations, target complementary mechanisms. But none replicate melatonin's specific receptor-mediated circadian signalling.

How Formulation Affects Melatonin Clearance

Melatonin's half-life is intrinsic to the compound once it enters circulation, but formulation determines how quickly. And how much. Reaches the bloodstream. Immediate-release tablets dissolve in the stomach and are absorbed primarily in the small intestine, producing peak plasma concentration within 30–60 minutes. Sublingual and buccal formulations bypass hepatic first-pass metabolism partially, increasing bioavailability to 60–80% compared to 10–30% for swallowed tablets. This higher bioavailability doesn't extend the half-life, but it does produce higher peak concentrations from the same nominal dose.

Extended-release melatonin uses polymer matrices or layered coatings to delay dissolution, releasing melatonin over 6–8 hours. The marketed advantage is sustained plasma levels throughout the night. The pharmacokinetic reality is more nuanced: extended-release formulations maintain low-level melatonin presence longer, but because the half-life remains 30–60 minutes, plasma concentration still peaks and declines repeatedly as each portion of the delayed dose is absorbed and metabolised. The net effect is a flattened, extended curve rather than a single sharp peak. Potentially beneficial for sleep maintenance, but not a workaround for melatonin's rapid hepatic clearance.

Liquid formulations and lozenges offer faster absorption than tablets, which may benefit individuals who need rapid sleep onset or have delayed gastric emptying. However, faster absorption also means faster clearance. The total duration of melatonin presence in the bloodstream is determined by elimination half-life, not absorption rate. Research-grade peptide delivery systems, like those used in nasal spray formulations such as Semax, demonstrate similar principles: route of administration affects bioavailability and Cmax, but intrinsic peptide half-life governs how long the compound remains active once absorbed. Formulation is a tool for optimising delivery. It doesn't fundamentally alter metabolic clearance.

What's the half-life of melatonin if taken properly? It's still 30–60 minutes. Formulation changes when and how much melatonin appears in your bloodstream, but once it's there, hepatic CYP1A2 enzymes metabolise it at the same rate. This is why timing remains the single most critical variable in melatonin supplementation strategy. Not the milligram amount or the delivery method. Understanding this allows you to match formulation to intent: immediate-release for sleep onset, extended-release for maintenance, sublingual for bioavailability. All constrained by the same underlying pharmacokinetic reality.